We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teleflex Incorporated (TFX - Free Report) presents investors with a clearer valuation argument, but not a clean execution story. The stock trades below its sub-industry, the Zacks Medical sector and the S&P 500 on forward earnings, while 2026 adjusted earnings guidance has moved higher.
Debt reduction and share repurchases strengthen the financial setup. Yet slower Vascular Intervention integration, unfinished divestiture work and margin pressure mean the valuation discount must be weighed against operating risk.
Why TFX's Valuation Looks More Reasonable
TFX trades at 14.49X forward 12-month EPS, compared with 26.88X for its sub-industry, 21.94X for the Zacks Medical sector and 20.37X for the S&P 500. That gap gives investors a lower entry multiple than the broader benchmarks.
Image Source: Zacks Investment Research
The stock also trades below its five-year median of 15.69X. Its five-year range spans 6.64X to 28.74X, however, so the current discount does not by itself resolve the execution issues that have pressured the business.
How Teleflex's Portfolio Reset Changes the Story
Teleflex completed the OEM divestiture in August for $1.5 billion in cash, with estimated after-tax proceeds of about $1.25 billion. The company repaid roughly $700 million of Term Loan A-2 debt, helping pro forma net leverage fall to about 1.9X from 2.8X at second-quarter end. It also repurchased $250 million of stock in the second quarter.
The Acute Care and Interventional Urology sale is still expected to close in the fourth quarter, subject to regulatory approval. Until that transaction closes and stranded costs are removed, part of the portfolio-reset benefit remains dependent on execution.
Why TFX's Earnings Outlook Has Improved
Teleflex raised 2026 adjusted earnings guidance to $6.90-$7.20 from $6.25-$6.55. Debt repayment should reduce interest expense, while the completed second-quarter repurchase and a planned $250 million accelerated repurchase can lower the share count.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings has increased 8.5% over the past four weeks. That revision trend reinforces the near-term earnings case, even though it does not erase the slower underlying revenue outlook.
Where Teleflex Still Faces Execution Risk
Management cut pro forma adjusted constant-currency revenue growth guidance to 3.5%-4.5% from 4.5%-5.5% because integration of the acquired Vascular Intervention business is taking longer than expected. Second-quarter adjusted operating margin fell 520 basis points to 19.6%, reflecting gross-margin pressure, acquisition-related operating costs and higher R&D spending. Tariffs also weighed on adjusted gross margin.
Competition adds another execution test. Medtronic plc (MDT - Free Report) began early commercial use of its Concerto Versa detachable coil for peripheral vascular embolization in May, while Boston Scientific Corporation (BSX - Free Report) reported positive pivotal data for its SEISMIQ 4CE coronary intravascular lithotripsy catheter. Teleflex must convert integration work and higher R&D spending into durable commercial gains.
TFX's Near-Term Signal Stays Constructive
The bottom line is that TFX offers a more reasonable valuation and an improving earnings setup, but the buy case remains conditional on execution. Balance-sheet progress is visible; a cleaner organic-growth and margin profile still needs to emerge.
TFX currently carries a Zacks Rank #2 (Buy). Its Value Score of B, Momentum Score of B and VGM Score of B support the near-term signal, while its Growth Score of C is more restrained. That combination supports investor interest without removing uncertainty around integration, divestiture completion and margin recovery.
View the Zacks #1 Rank List
Image: Bigstock
Is TFX a Buy Now as Valuation Improves but Execution Risks Remain?
Key Takeaways
Teleflex Incorporated (TFX - Free Report) presents investors with a clearer valuation argument, but not a clean execution story. The stock trades below its sub-industry, the Zacks Medical sector and the S&P 500 on forward earnings, while 2026 adjusted earnings guidance has moved higher.
Debt reduction and share repurchases strengthen the financial setup. Yet slower Vascular Intervention integration, unfinished divestiture work and margin pressure mean the valuation discount must be weighed against operating risk.
Why TFX's Valuation Looks More Reasonable
TFX trades at 14.49X forward 12-month EPS, compared with 26.88X for its sub-industry, 21.94X for the Zacks Medical sector and 20.37X for the S&P 500. That gap gives investors a lower entry multiple than the broader benchmarks.
Image Source: Zacks Investment Research
The stock also trades below its five-year median of 15.69X. Its five-year range spans 6.64X to 28.74X, however, so the current discount does not by itself resolve the execution issues that have pressured the business.
How Teleflex's Portfolio Reset Changes the Story
Teleflex completed the OEM divestiture in August for $1.5 billion in cash, with estimated after-tax proceeds of about $1.25 billion. The company repaid roughly $700 million of Term Loan A-2 debt, helping pro forma net leverage fall to about 1.9X from 2.8X at second-quarter end. It also repurchased $250 million of stock in the second quarter.
The Acute Care and Interventional Urology sale is still expected to close in the fourth quarter, subject to regulatory approval. Until that transaction closes and stranded costs are removed, part of the portfolio-reset benefit remains dependent on execution.
Why TFX's Earnings Outlook Has Improved
Teleflex raised 2026 adjusted earnings guidance to $6.90-$7.20 from $6.25-$6.55. Debt repayment should reduce interest expense, while the completed second-quarter repurchase and a planned $250 million accelerated repurchase can lower the share count.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings has increased 8.5% over the past four weeks. That revision trend reinforces the near-term earnings case, even though it does not erase the slower underlying revenue outlook.
Where Teleflex Still Faces Execution Risk
Management cut pro forma adjusted constant-currency revenue growth guidance to 3.5%-4.5% from 4.5%-5.5% because integration of the acquired Vascular Intervention business is taking longer than expected. Second-quarter adjusted operating margin fell 520 basis points to 19.6%, reflecting gross-margin pressure, acquisition-related operating costs and higher R&D spending. Tariffs also weighed on adjusted gross margin.
Competition adds another execution test. Medtronic plc (MDT - Free Report) began early commercial use of its Concerto Versa detachable coil for peripheral vascular embolization in May, while Boston Scientific Corporation (BSX - Free Report) reported positive pivotal data for its SEISMIQ 4CE coronary intravascular lithotripsy catheter. Teleflex must convert integration work and higher R&D spending into durable commercial gains.
TFX's Near-Term Signal Stays Constructive
The bottom line is that TFX offers a more reasonable valuation and an improving earnings setup, but the buy case remains conditional on execution. Balance-sheet progress is visible; a cleaner organic-growth and margin profile still needs to emerge.
TFX currently carries a Zacks Rank #2 (Buy). Its Value Score of B, Momentum Score of B and VGM Score of B support the near-term signal, while its Growth Score of C is more restrained. That combination supports investor interest without removing uncertainty around integration, divestiture completion and margin recovery.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.